Topcon launches OMS-710 Operation Microscope

Article

A surgical microscope designed specifically for cataract and anterior segment surgery - the OMS-710 Operation Microscope - has been launched by Topcon Medical Systems, Inc.

A surgical microscope designed specifically for cataract and anterior segment surgery - the OMS-710 Operation Microscope - has been launched by Topcon Medical Systems, Inc.

The OMS-710 has a colour temperature filter and features newly designed optics that minimize flare, provide improved contrast, and increase the depth of field while supplying a superior red reflex.

As the OMS-710 weighs 27% less than earlier models of surgical microscope, the manufacturers believe it is ideally suited to cataract and anterior segment surgery. An optional 0º rotatable assistant microscope facilitates anterior segment surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.